Use of UK plasma for the manufacture of five further plasma derived medicinal products and vCJD risk

The Medicines and Healthcare products Regulatory Agency (MHRA) published a review of the safety of albumins manufactured from UK-sourced plasma with respect to variant Creutzfeldt-Jakob disease (vCJD) risk in August 2023. A further review of the safety of five additional plasma derived medicinal products (Fibrinogen, Prothrombin Complex Concentrates (PCCs), C1 Esterase Inhibitor, Factor X and Protein C) manufactured from UK-sourced plasma with respect to vCJD risk has now been completed, with the results published in July 2026.